Hematology/Oncology Education and CME

  • Top Picks
    • MPN Updates
    • In My Setting: Sarcoma
    • Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia
    • Video Perspectives: Colorectal Cancer Studies and Treatments

Select a Topic

  • FILTER BY:
MPN Updates

MPN Updates

This electronic newsletter is sponsored by Incyte Corp. through a third-party independent grant.

April 19, 2016

As the standards of care for patients with myeloproliferative neoplasms (MPNs) continue to evolve, physicians must stay informed on current research and treatment…

go to activity»
Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia.
CME

Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia

Supported by an educational grant from Bristol-Myers Squibb Company.

March 31, 2016

The advent of tyrosine kinase inhibitor therapy has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Expiration Date: 3/15/2017
Credit Type(s): CME | Credit: 0.25

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease, beginning as increasing prostate specific antigen (PSA)…

go to activity»
Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going
CME

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Expiration Date: 2/25/2017
Credit Type(s): CME | Credit: 1.25

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with advanced disease, and prognosis has been poor…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Expiration Date: 1/15/2017
Credit Type(s): CME | Credit: 0.25

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML). Although imatinib has been the standard of care, second…

go to activity»
Healio - Hematology/Oncology  Education Lab
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 12/15/2016
Credit Type(s): CME | Credit: 1.5

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small cell lung cancer (NSCLC); approximately 70% of…

go to activity»
In My Setting: Sarcoma

Read what three clinicians have to say about the current state of sarcoma treatment options….

go to activity»
Video perspectives

Video perspectives include topics such as colorectal cancer treatments currently in development that could improve patient outcomes and risk factors associated with…

go to activity»
HemOnc IMS Palliative Care

Catch up with three clinicians as they provide insightful information on the topic of palliative care….

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Expiration Date: 2/15/2017
Credit Type(s): CME | Credit: 0.25

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin present on the surface of the platelet membrane…

go to activity»
Healio - Hematology Oncology Education Lab
CMEVIDEO

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

Expiration Date: 1/11/2017
Credit Type(s): CME | Credit: 1

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this disease has been revolutionized with the development of…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Expiration Date: 12/15/2016
Credit Type(s): CME | Credit: 0.25

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or multiple (multicentric) lymph nodes. This…

go to activity»
MPN Updates

MPN Updates

This electronic newsletter is sponsored by Incyte Corp. through a third-party independent grant.

April 19, 2016

As the standards of care for patients with myeloproliferative neoplasms (MPNs) continue to evolve, physicians must stay informed on current research and treatment…

go to activity»
In My Setting: Sarcoma

Read what three clinicians have to say about the current state of sarcoma treatment options….

go to activity»
Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia.
CME

Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia

Supported by an educational grant from Bristol-Myers Squibb Company.

March 31, 2016

The advent of tyrosine kinase inhibitor therapy has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires…

go to activity»
Video perspectives

Video perspectives include topics such as colorectal cancer treatments currently in development that could improve patient outcomes and risk factors associated with…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Expiration Date: 3/15/2017
Credit Type(s): CME | Credit: 0.25

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease, beginning as increasing prostate specific antigen (PSA)…

go to activity»
HemOnc IMS Palliative Care

Catch up with three clinicians as they provide insightful information on the topic of palliative care….

go to activity»
Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going
CME

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Expiration Date: 2/25/2017
Credit Type(s): CME | Credit: 1.25

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with advanced disease, and prognosis has been poor…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Expiration Date: 2/15/2017
Credit Type(s): CME | Credit: 0.25

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin present on the surface of the platelet membrane…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Expiration Date: 1/15/2017
Credit Type(s): CME | Credit: 0.25

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML). Although imatinib has been the standard of care, second…

go to activity»
Healio - Hematology Oncology Education Lab
CMEVIDEO

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

Expiration Date: 1/11/2017
Credit Type(s): CME | Credit: 1

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this disease has been revolutionized with the development of…

go to activity»
Healio - Hematology/Oncology  Education Lab
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 12/15/2016
Credit Type(s): CME | Credit: 1.5

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small cell lung cancer (NSCLC); approximately 70% of…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Expiration Date: 12/15/2016
Credit Type(s): CME | Credit: 0.25

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or multiple (multicentric) lymph nodes. This…

go to activity»
Improving Patient Outcomes in Chronic Myeloid Leukemia: Montioring and Managing Response and Resistance
CME

Improving Patient Outcomes in Chronic Myeloid Leukemia: Monitoring and Managing Response and Resistance

This activity is supported by an educational grant from Pfizer Inc.

December 11, 2015

Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the bone marrow, accounting for 15% of adult leukemias. Targeted therapy with tyrosine kinase…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Myelofibrosis

No commercial support for this activity.

Expiration Date: 11/15/2016
Credit Type(s): CME | Credit: 0.25

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature cells, resulting in fibrosis and chronic inflammation…

go to activity»
Healio - Hematology Oncology
CMEVIDEO

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 11/9/2016
Credit Type(s): CME | Credit: 1

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small cell lung cancer (NSCLC); approximately 70% of…

go to activity»
Updates from Vienna 2015 – Highlights in Hematologic Malignancies
CME

Updates from Vienna 2015 – Highlights in Hematologic Malignancies

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 10/29/2016
Credit Type(s): CME | Credit: 1.25

The management of patients with hematologic malignancies—from diagnosis to treatment decisions—can represent a challenge for hematologists and oncologists due to several…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

Expiration Date: 10/15/2016
Credit Type(s): CME | Credit: 0.25

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis, characterization and treatment of the disease…

go to activity»
World Lung Updates: Immunotherapy in NSCLC
CMEVIDEO

World Lung Updates: Immunotherapy in NSCLC

This activity is supported by an educational grant from Genentech, Inc and Merck & Co., Inc.

Expiration Date: 9/27/2016
Credit Type(s): CME | Credit: 1.25

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung malignancies. Approximately 70% of…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Pancreatic Cancer

No commercial support for this activity.

Expiration Date: 9/15/2016
Credit Type(s): CME | Credit: 0.25

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death. This CME activity will focus on the diagnosis and…

go to activity»
Updates in Immunotherapy – Philadelphia 2015
CMEVIDEO

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

Expiration Date: 8/17/2016
Credit Type(s): CME | Credit: 0.75

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval of the programmed death-1 (PD-1) inhibitor…

go to activity»
Immunotherapy Updates 2015: FOCUS on NSCLC
CME

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 8/15/2016
Credit Type(s): CME | Credit: 1.5

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

Expiration Date: 8/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer….

go to activity»
Diabetic Eye Disease Consults: Volume 1, Number 1
CME

Updates in Melanoma 2015: Entering a New Therapeutic Era

This activity is supported by an educational grant from Merck & Co., Inc.

Expiration Date: 8/1/2016
Credit Type(s): CME | Credit: 1.25

The incidence of melanoma, an aggressive disease that accounts for approximately 75% of skin-cancer-related deaths, is continuing to increase worldwide. Historically…

go to activity»
Immunotherapy Updates 2015: FOCUS on NSCLC
CMEVIDEO

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 7/28/2016
Credit Type(s): CME | Credit: 0.75

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Multiple Myeloma

No commercial support for this activity.

Expiration Date: 7/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with multiple myeloma….

go to activity»
M608ActivityImage
CME

PosterPerspectives: NSCLC Posters and Abstracts from Chicago

This activity is supported by an independent educational grant from AstraZeneca.
Supported by an educational grant from Genentech.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

June 30, 2015

The following abstracts and posters were curated from all the posters presented at the 2015 American Society of Clinical Oncology meeting. The posters look at a several…

go to activity»
Tailored Therapies for Myelodysplastic Syndromes
CME

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Expiration Date: 6/29/2016
Credit Type(s): CME | Credit: 1

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical manifestations. The main clinical complication in MDS is…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

Expiration Date: 6/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia….

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Melanoma

No commercial support for this activity.

Expiration Date: 5/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with melanoma….

go to activity»
Enhancing Patient and Health Care Team Communications: Paving the way for success

Enhancing Patient and Health Care Team Communications: Paving the way for success

This HemOnc Today supplement is produced by SLACK Incorporated and sponsored as an educational service by Cephalon, a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.

December 1, 2011

Effective communication between health care providers and patients diagnosed with cancer is an essential part of the treatment process. Communicating effectively ensures…

go to activity»